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Alberto Frutos Pérez-Surio
Abstract
Antidotes are essential medicines for the management of some of the emergen-
cies attended in the hospital environment, and the speed of administration can be 
a key element for the survival of the patient. The Hospital Pharmacy Services are 
responsible for guaranteeing its availability. However, this availability can be affected 
by some aspects like the frequency of presentation of an intoxication in a geographi-
cal area, urgency in administration, difficulties of acquisition, cost, and period of 
validity, among others. In Spain, a web-based application was developed (www.
redantidotos.org). It includes a public site with general information, an updated 
antidote guide and a section where non-urgent toxicological consultations could 
be submitted. Design a virtual antidote network between hospitals could be really 
useful to help the location online of the hospitals that stocked those antidotes with 
the highest difficulty in terms of availability, and ensured that the medication will 
be loaned in case of necessity. Therefore, it is necessary to create a tool that facilitates 
the exchange of antidotes between hospitals and ensures their availability. The aim is 
to continue improving communication between professionals involved in intoxica-
tion management at national, European and international level, sharing knowledge 
and improving the care we offer to our patients.
Keywords: antidotes, poisonings, virtual network, emergency, hospital pharmacy 
services
1. Introduction
1.1 Antidotes
Poisoning is the second leading cause of injury-related morbidity and mortality in 
the United States, with more than 2.4 million toxic exposures reported each year [1].
Antidotes, remedies or agents counteracting or neutralizing the action of poisons 
(MeSH and Emtree definitions, from Dorland’s Medical Dictionary, 32nd edition), 
apply their useful impacts through an assortment of components, including the 
development of an inactive complex with the venom, the speeding up of venom 
detoxification, the decrease of venom transformation rate to a progressively dangerous 
compound, rivalry with venom for fundamental receptor locales, blockage of basic 
receptors through which lethal impacts are intervened, and avoidance of venom impact. 
There are explicit antidotes for few toxins, and a couple of counteractants are routinely 
utilized in clinical practice. These are acetylcysteine, naloxone and flumazenil.
Antidotal therapy is a critical aspect of the poisoning management in emergency 
setting: prompt availability and sufficient amount are essential, particularly when 
these molecules represent life-saving therapy for the acute poisoned patient.
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Pharmacists can help reduce morbidity and mortality due to poisonings and 
overdoses by recognizing the signs exposure, guiding emergency room staff on the 
appropriate use of antidotes and supportive therapies, helping to ensure appropri-
ate monitoring of patients for antidote response and adverse effects and managing 
the procurement and stocking of antidotes to ensure their timely availability [2].
1.2 Justification and background
Antidotes are essential medicines for the management of some of the emergen-
cies attended in the hospital environment, and the speed of administration can be 
a key element for the survival of the patient. The Hospital Pharmacy Services are 
responsible for guaranteeing its availability [3–6].
However, it can be affected by several causes:
• Frequency of presentation of an intoxication in a geographical area
• Urgency in administration
• Difficulties of acquisition
• Cost
• Period of validity
Therefore, it is necessary to create a tool that facilitates the exchange of antidotes 
between hospitals and ensures their availability.
For example, in other countries like in the USA, to appropriately prepare for 
bioterrorism response, the governmental Agency that optimally provides the sur-
veillance and planning guidance is the Centers for Disease Control and Prevention 
(CDC). Pharmacists can play a key role in reducing poisoning and overdose injuries 
and deaths by assisting in the early recognition of toxic exposures and guiding emer-
gency personnel on the proper storage, selection, and use of antidotal therapies. The 
clinical pharmacist for a hospital is creating a protocol for the pharmacy department 
in the event of a biological disaster. Five elements that are critical to the protocol 
follow the National Preparedness Goal (NPG) created to prepare the United States 
for threats that pose risks to the nation, including acts of terrorism. The five mission 
areas that were identified in order to achieve the NPG are: Prevention, protection, 
mitigation, response, and recovery. The pharmacy department of a given hospital 
stores a Strategic National Stockpile (SNS) cache for use in a disaster. The person 
that authorizes deployment of the stockpile is the State governor’s office, and there-
after, Pharmacy director and Hospital Incident Command System (HICS).
Inadequate stock or insufficient number of antidotes is a common and diffused 
problem in the Emergency Departments in many countries. In Italy, based on this 
consideration, from 2003 to 2012 two National surveys has been conducted from 
Pavia Poison Control Centre (Pavia-PCC) with the grant of the Italian Ministry 
of Health. The aim of these surveys was to evaluate antidotes availability in the 
Emergency Services (PCCs, EDs, intensive care units) and Hospital Pharmacies of 
the National Health System (NHS) throughout the Italian country. As a result of this 
initiative, since 2006, the collected data were organized in a specific “National data-
base of antidotes” (BAnDA), available online (www.cavpavia.it) for the registered 
services that provided their data and with optimal and effective results.
Regarding Spain, in July 2015, the Xarxa d’Antídots de Catalunya was created 
to interconnect public and private hospitals throughout the community. It includes 
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the provision, in these centers, of 18 antidotes for which there may be problems of 
availability due to the aforementioned factors.
The experience of the first few years has been very positive, both in terms of 
the number of hospitals adhered to and the toxicological consultations received, 
and loans made. For this reason, and with the intention of extending this project 
throughout the country, the Antidote Network was created. The Balearic Islands has 
been the first community to join and it is planned to expand with more regions in 
the near future.
1.3 Objectives
• To describe and to make a revision of Antidotes and their importance as an 
essential drug for management of acute intoxications.
• To give several evidences that the availability problems about stocking of 
antidotes in hospitals are an important concern, due to the lack of a National 
Regulation.
• To show the importance and responsibility that Pharmacy Departments are for 
warranting an optimal qualitative and quantitative stock of these drugs.
• In this context, the main objective is to propose a detailed review of the 
Antidotes Network that has been created in the Spanish territory.
2. Methodology
Within the framework of the Catalan Society of Clinical Pharmacy, a working 
group formed by pharmacists and doctors with experience in the field of Clinical 
Toxicology was created to develop the network. First, the group prepared a docu-
ment with recommendations on the storage of antidotes according to the complex-
ity and location of the hospital. An online application was then intended to be 
utilized as a specialized instrument between centers.
The application collects information on 15 antidotes, selected according to 
criteria of availability, urgency, frequency of use or cost (fragments of digoxin 
antibodies, methylene blue, deferoxamine, dimercaprol, calcium sodium edate, 
ethanol, physostigmine, fomepizole, glucagon, hydroxocobalamin, pyridoxine, 
pralidoxime, silibinin, botulinum antitoxin and snake venom antiserum). This tool 
provides information on the stock of each center (including the expiration date) 
and facilitates the loan of antidotes between hospitals.
3. Results
3.1 Antidotes network
The online application “Red de Antidotos” was propelled in July 2015. It has an 
open region with data about the task and offers the probability of non-dire toxico-
logical discussions to the specialists of the gathering, and a private zone available 
with username and secret key for the focuses that have joined the network. So 
far 34 Catalan clinics offering crisis care have been fused. In each inside there is a 
drug specialist and a specialist from the Emergency Department in charge of the 
network. These figures are designated “farmatox” and “urgetox”. The “farmatox” 
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is responsible for the support of the stocks, refreshes the developments of medica-
tions and arranges and loan antidotes between emergency clinics. The “urgetox” 
builds up the elements of toxicology referent of the Emergency Department.
The network of antidotes is a really intuitive and helpful device. The private 
region is separated into four segments. The Antidote segment contains data on 
antidotes, which can be counseled on the web. It is a powerful list, kept up by the 
individuals from the gathering, which gathers information on toxicological signs, 
measurements with the best agreement for the two grown-ups and kids, accessible 
definitions, perceptions on organization, strength, unfriendly responses and differ-
ent contemplations to be considered, just as the prescribed amounts to be put away 
relying upon the multifaceted nature of every medical clinic.
The Antidote Stock Management segment gathers the accessible measure of 
antitoxins in the network put away in every emergency clinic. The application 
permits the “farmatox” to enter any section and leave development. Every passage 
must include: medicine, number of units, bunch, lapse date and sort of develop-
ment. For the last mentioned, two sorts of passage developments have been char-
acterized (buy of drugs and return of the advance to another medical clinic), and 
three kinds of leave developments (claim use, termination and credit).
All developments for stock refreshing (credit developments just as for possess 
use) must be done physically by the drug specialist mindful in every emergency 
clinic. To encourage this stock upkeep, the application enables you to print a record 
with the units entered for each clump and the lapse date for each group. Lapsed 
units are featured in red.
The application enables you to scan for antidotes by drug or by medical clinic, 
in the area of the guide that demonstrates the data of the considerable number of 
emergency clinics incorporated into the network. At the point when the inquiry is 
done by clinic, the accompanying information can be counseled on the guide: name 
of the “farmatox” and the “urgetox”, address, phone, email, fax and opening times 
of the Pharmacy, Department and phone of the Emergency Unit. It likewise demon-
strates every one of the antidotes accessible in the inside, with their number of units 
and the following expiry date. At the point when the antitoxin search is played out, 
all clinics in which the cure is accessible will be shown, just as the quantity of acces-
sible units and the following termination date.
3.2 Centers
The network was first implemented in Catalonia and now the project is being 
extended to other Spanish regions (currently it has been implemented in three 
out of 17 regions, Figure 1), with the aim to continue improving communication 
between professionals involved in intoxication management, sharing knowledge 
and improving the care we offer to our patients.
There are presently 63 Spanish emergency clinics incorporated into the 
Antidotes Network. It has been utilized multiple times to find a remedy that was 
vital and to apply for an advance between focuses. Up until this point, 13 counter-
actants have been engaged with these developments. The most requested drugs are 
represented in the image below (Figure 2). Likewise, proposals on stock acces-
sibility and utilization of antidotes as indicated by the multifaceted nature of the 
medical clinic were distributed and are accessible in the Emergencias Journal.
3.3 Antidotes stocks
As a result of this project, “the Antidotes Guide” was published, that includes 
recommendations for the availability of 38 antidotes depending on the level of 
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complexity of the hospitals and information on toxicological indications, posology 
and other observations of interest.
In the private part of the Antidotes Network, the stocks of the adhered hospitals 
are available for those antidotes in which availability problems may occur. Currently 
there are 18 antidotes included in the private part of the Network (Table 1).
Note also that the list of antidotes included in the network will change according 
to the needs of its hospitals, any epidemiological changes in poisoning, the launch 
of new antidotes, and problems for supply of others.
3.4 Consultations section
The consultations section is a tool very useful that the Antidote Network offers to 
any Health Professional the possibility of carrying out various types of toxicological 
consultations, as: (i) intoxications in which an antidote could be used, (ii) antidotes 
Figure 1. 
Centers of the Antidotes Network in Spain.
Figure 2. 
Most request drugs. Source: Aguilar-Salmerón et al [7].
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Antidotes Commercial presentations Initial dosing
Antidigoxin antibodies Digifab® 40 mg vial
Refrigerator. Foreigner
IV 40 mg per 0.5 mg digoxin. If 
unknown digoxin quantity 400 mg (10 
vials). To reconstitute with 4 mL of 
water + 250 mL PS 30 minutes inf. It 
may be necessary to repeat doses
Dantrolene Dantrolen® 20 mg vial IV 2.5 mg/kg (each vial in 3 min) 
preferably via central. Maximum doses 
reached 10 mg/kg
Deferoxamine Desferin® vial 500 mg IM 2 g in 10 mL Water or IV 15 mg/
Kg/h (max. 80 mg/Kg/24 h)
Defibrotide Defibrotide® 200 mg/2.5 mL 
vial
IV 6.25 mg/kg/h in 2 h
Dimercaprol (bal, British 
anti-lewisite)
Dimercaprol® amp. 200 mg 
c/12 amp 2 mL. Foreigner
IM 3 mg/Kg/4 h for 2 days
Calcium edetate sodium 
(EDTA)
Calcium Edetate sodium® 
amp.500 mg/10 mL c/10 amp.
Foreigner
IV 1000 mg in 250 mL SF 6 hours 
infusion. Repeat every 12 h for 5 days
Ethanol (absolute 
ethanol)
Absolute ethanol® amp 10 mL
Pharmaceutical Compounding
IV. 1 mL/Kg in D 5% 50 mL in 1 h. 
Continue with 0.1 mL/Kg/h. If 
alcoholic, double dose. Requires 
analytical control e/6h
Physostigmine Anticholium® 2 mg/5 mL amp IV 1–2 mg in 2 min. Repeat each bolus 
every 10–30 min. Alternatively: 2 mg/h 
up to a maximum of 8 mg/h
Fomepizole Fomepizol® vial 100 mg IV Loading dose of 15 mg/kg in 
100–250 mg of NaCl 0.9% or D 5% and 
administered in 30–45 min
Glucagon Glucagon Gen Hypokit® 1 mg 
syringe
IV 5 mg in 1 min. Repeat, if needed, in 
10 min
Glucarpidase Voraxazane® 1000 U vial IV 50 U/kg in 5 min injection
Hydroxocobalamin Cyanokit® 5 g vial IV 5 g in 10 min (2.5 g if <35 Kg). If 
cardiac arrest 10 g in 10 min. If after 
1 h there is no change, 5 more grams in 
15 min
Idarucizumab Praxbind® 2.5 g injectable 
solution
IV 5 g (2 vials) in two consecutive 
infusions or in one infusion
Pralidoxime (pam) Contrathion® vial 
200 mg/10 mL c/10 vials-amp. 
Foreigner
IV 1 g in 100 mL G 5 % 1 h infusion. If 
necessary, continue with the same dose 
every 6 h for 2–3 days.
Silibinin Legalon® vial 350 mg IV 5 mg/kg in 500 mL NaCl 0.9% or D 
5% in 2 h. Repeat each 6 h (3–4 days)
Antibotulinum serum Botulism Antitoxin Heptavalent 
A, B, C, D, E, F, G (BAT) 50 mL 
injectable solution
IV dilute 1 vial 1:10 and administer at 
0.5 mL/min during 30 min. Maximum 
rate of 2 mL/min
Antiophidic serum Snake venom antiserum 
(Bulbio®) vial 100 UI (5 mL). 
Foreigner
One dose corresponds to 100 IU (1 vial). 
First dose given via SC at the site of the 
sting, second dose via IM in the buttock.
Further doses may be necessary at a 
later time as clinically determined.
Uridine triacetate Vistonuridine® 10 g sachet PO 10 g each 6 h, 20 doses
Table 1. 
Antidotes included in the private part of the Network.
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that could be used in some types of poisonings, (iii) agents used for digestive, 
cutaneous or ocular decontamination (iv) recommendations on qualitative and 
quantitative availability of antidotes.
Also, this section offers the possibility that the answer to some of these questions 
can be found by the reader in the Antidote Guide that can be found in this website.
For urgent medical consultations due to poisonings and toxicological emergen-
cies, it is possible to contact by telephone the Toxicological Information Service 
of the National Institute of Toxicology and Forensic Sciences as this Service offers 
toxicological advice 24 h a day, 365 days a year. Otherwise, for non-urgent consulta-
tions on Clinical Toxicology, pharmacological aspects of antidotes or on drugs that 
can cause intoxications, it is possible to contact the experts of the Group of anti-
dotes, specialized in assistance to acute intoxications in both adults and pediatrics, 
via an official email published on the official website.
4. Discussion
It is necessary to guarantee an adequate stock of antidotes in those hospitals 
managing poisoned patients; however, this is not always simple to realize.
Making a database of refreshed supplies of antitoxins open to all medical clinics 
overseeing clinic crises is definitely not another thought. New Zealand emergency 
clinics have just recommended its creation as an answer for the inadequacies found 
[7, 8]. Similarly, the “Centro Antiveleni di Pavia - Centro Nazionale di Informazione 
Tossicologica” made the Banca Dati Nazionale degli Antidoti (BaNdA), in light of 
an investigation of the accessibility of antidotes in Italian Emergency Units, among 
others [9–16]. It is an on-line stage that permits to discover refreshed information 
on the subjective and quantitative accessibility of counteractants in all the clinic 
units required, to look for a particular antitoxin by city or area and to get to all the 
contact information important to apply for an advance.
Some information on antitoxins and how they are arranged through Spanish anti-
dote network as antitoxins are always a problem for both developing and developed 
countries. Particularly, some information on botulinum antitoxins and anti-venoms:
Botulism Antitoxin Heptavalent—A, B, C, D, E, F, G (BAT), solution for injec-
tion: Adult dosage administration: Dilute the vial in a ratio of 1:10 and administer 
at a speed of 0.5 mL/min for 30 min and increase to double the speed every 30 min 
up to a maximum of 2 mL/min. For child dosage: Between 20 and 100% of the 
vial according to body weight. In children under 1 year the dose is 10% of the vial 
regardless of body weight. For administration: Dilute the vial in a ratio of 1:10 and 
administer at a speed of 0.01 mL/kg/min and increase by 0.01 mL/kg/min every 
30 min to a maximum of 0.03 mL/min without exceeding adult rates. For dilution: 
Since the filling volume of each vial varies depending on the lot number (approxi-
mately 10–22 mL per vial), 90–200 mL of saline solution will be required for 
dilution. Conservation conditions: Store frozen or below ≤−15°C until used. Once 
thawed, it can be stored at 2–8°C for up to 36 months or up to 48 months from the 
date of manufacture (whichever comes first). Do not refreeze the vial. Administer 
the drug at room temperature. To defrost it, leave it at room temperature for 1 h and 
then immerse it in a bath of water at 37°C until it defrosts completely.
Snake Venom Antiserum (Bulvio® and Viperfav®): Adult and child dosage:
• Viperfav: IV Perfusion of 4 mL of serum (1 vial) in 100 mL SF at 50 ml/h.
• Snake Venom Antiserum: 100 IU (5 mL) via SC, followed by a second IM 
dose in the buttock. 1,2 or more IM doses may be necessary depending on the 
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patient’s condition and on the second and third days 1 or 2 more doses may 
be needed. Viperfav® has a low risk of anaphylactic reactions. On the other 
hand, in the case of Snake Venom Antiserum® it is recommended to carry out 
a hypersensitivity test prior to its administration.
Building up a network of antitoxins can improve correspondence between 
focuses that oversee harmed patients, adjust and institutionalize antidotes assets in 
various focuses, and accelerate credits if essential. Eventually, it can improve the 
nature of consideration for harmed patients.
5. Conclusions
Antidote Network could allow improved communication between centers 
involved in the management of poisoned patients, help in adjusting and harmoniz-
ing antidotes stock and accelerate antidote borrowing, if required.
Furthermore, this Antidote Network provide prompt and easy access to anti-
dotes (especially expensive and rare-use ones), to rapidly find them in the nearby 
hospitals or regions (avoiding lengthy and expensive transport), and it is useful also 
to optimize antidote stockpiles with saving of resources.
As future proposals it would be very convenient to expand the network through-
out the national territory and implement it in other countries, which would allow an 
increase in the quality of life of the patient and an improvement in public health.
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